EditorialPatent Ductus Arteriosus: Evidence for and against Treatment
Section snippets
Prophylactic trials
Morbidities affected by the PDA (or its treatment) that could be detected in prophylactic trials are those that occur between birth and the time of backup treatment (2-3 days after birth) (Figure). Both, the individual prophylactic trials and a meta-analysis of their results (reviewed in references 9 and 10) consistently show that prophylactic use of indomethacin increases the effectiveness of pharmacologic closure and decreases the need for surgical ligation, decreases the incidence of early,
Symptomatic treatment trials
Like the prophylactic trials, the symptomatic treatment trials can only detect PDA-related morbidities that occur between the time of initial treatment (>2 days after birth) and the time of backup closure (Figure). In these trials, infants were exposed to a symptomatic PDA for varying time spans before backup closure was invoked (mean [range] = 5 [1-14] days). For the purposes of discussion, we analyzed only those trials that waited at least 6 days (mean = 9 ± 3 days) before resorting to backup
Pulmonary morbidity
Five of the seven trials that reported pulmonary morbidity8, 12, 13, 14, 15, 16, 17 (and a meta-analysis of the seven trials) showed that exposure to a symptomatic PDA, for at least 6 days, prolonged the need for supplemental oxygen and/or mechanical ventilation. Information about longer exposures to a PDA can be found in studies of preterm baboons. These studies provide evidence for more long lasting pulmonary morbidity following exposure to a persistent PDA. Premature newborn baboons, exposed
Necrotizing enterocolitis
There is little evidence to support or refute the role of a PDA in necrotizing enterocolitis (NEC). A meta-analysis of the trials8, 13, 15, 16, 18 that delayed backup treatment for at least 6 days showed that early treatment of a PDA may decrease the incidence of NEC, but only among infants <1000 g birth weight. This analysis has some uncertainty because it is heavily weighted by a single study18; no significant association between a PDA and NEC was found when this study was removed from the
Retinopathy of prematurity (ROP)
No causal role has been found for a PDA in ROP.
Morbidities associated with indomethacin
Any discussion of PDA treatment must consider the possibility of treatment-related morbidities. Although none of the treatment trials were specifically designed to examine the incidence of morbidities caused by indomethacin or surgery, the prophylactic treatment trials do provide some information about those associated with indomethacin. In these trials, <50% of control group infants were exposed to indomethacin (compared with 100% in the prophylactic group) (see reference 9). Therefore, one
Morbidities associated with ligation
What happens when pharmacologic treatment fails to close the PDA? Surgical ligation of a PDA is associated with its own set of morbidities: thoracotomy, pneumothorax, chylothorax, infection, and vocal cord paralysis. More than 50% of infants with birth weights ≤1000 g will require inotropic support for profound hypotension during the postoperative period.30 In addition, neonatal transport to another facility may be required if surgical expertise is not readily available. The article by Kabra et
References (36)
- et al.
Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants
J. Pediatr
(1978) Commentary: recommendations for the postnatal use of indomethacin. An analysis of four separate treatment strategies
J Pediatr
(1996)- et al.
Indomethacin therapy on the first day of life in infants with very low birth weight
J Pediatr
(1985) - et al.
Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very low birth weight infants with symptomatic patent ductus arteriosus
J Pediatr
(1983) - et al.
Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants
J Pediatr
(2005) - et al.
Effects of indomethacin on cerebral haemodynamics in very preterm infants
Lancet
(1990) - et al.
Prevention of intraventricular hemorrhage by indomethacin in male preterm infants
J Pediatr
(2004) - et al.
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study
J Pediatr
(1983) - et al.
Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2
Proc Natl Acad Sci U S A
(2001) Natural history of persistent ductus arteriosus
Br Heart J
(1968)
Is surgical ligation of patent ductus arteriosus necessary?The Western Australian experience of conservative management
Arch Dis Child Fetal Neonatal Ed
Long-term follow-up of dogs with patent ductus arteriosus
J Small Anim Pract
Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis
N Engl J Med
Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated?
Curr Opin Pediatr
Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants
J Pediatr
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants
Cochrane Database Syst Rev
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants
Cochrane Database Syst Rev
Effect of early indomethacin on ventilatory status of preterm infants with symptomatic patent ductus arteriosus
Pediatr Res
Cited by (127)
Patent Ductus Arteriosus in the Preterm Infant
2023, Avery's Diseases of the NewbornOutcomes of Extremely Premature Infants Comparing Patent Ductus Arteriosus Management Approaches
2021, Journal of PediatricsPremature infants with patent ductus arteriosus: Postnatal growth according to type of management
2021, Pediatrics and Neonatology
Supported by grants from U.S. Public Health Service (NIH grants HL46691, HL56061) and by a gift from the J and B Gates Foundation.